AYTU BIOPHARMA, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Aytu BioPharma, Inc. on July 10, 2023. The report discloses a material event regarding the company's primary product, Cotempla XR-ODT, under Item 7.01 (Regulation FD Disclosure).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a disclosure of a regulatory event rather than a financial performance report.
Material Changes and Events
- Regulatory Submission: On July 10, 2023, Aytu BioPharma announced the submission of a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA).
- Subject Matter: The submission concerns the transfer of the manufacturing site for Cotempla XR-ODT.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the standard regulatory process associated with a manufacturing site transfer. The press release attached as Exhibit 99.1 contains the full details of the announcement.
Investor Verification Checklist
- Verify the status of the Cotempla XR-ODT manufacturing site transfer with the FDA.
- Review the attached press release (Exhibit 99.1) for specific timelines regarding the site transfer approval.
- Monitor subsequent filings for any impact on product supply or commercial operations resulting from this transfer.